Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.790
+0.060 (3.47%)
At close: Sep 26, 2025, 4:00 PM EDT
1.840
+0.050 (2.79%)
After-hours: Sep 26, 2025, 7:05 PM EDT
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
64.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -77.46K | -58.40% |
| Dec 31, 2022 | 132.64K | -1.29K | -0.96% |
| Dec 31, 2021 | 133.93K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GANX News
- 4 days ago - Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 - GlobeNewsWire
- 9 days ago - Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease - GlobeNewsWire
- 23 days ago - Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation - GlobeNewsWire